Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon Sees 6.9% Sales Growth on Latuda, Diabetes Med; Name Change Announced
May 13, 2021
- Eisai Logs 58.8% Drop in Operating Profit as Merck Milestone Dips on Lenvima Miss
May 13, 2021
- Sawai Group Aims to Double Sales to 400 Billion Yen by FY2030: New Long-Term Vision
May 13, 2021
- 300 Million Yen Fine Sought for Alfresa Too, Verdict on June 30: Bid-Rigging Trial
May 13, 2021
- Ono Nets 5.8% Revenue Growth in FY2020 on Opdivo, Forxiga
May 12, 2021
- Takeda’s FY2020 Profits Jump on Non-Core Divestitures, Post-Shire Cost Synergies
May 12, 2021
- Ono Chief Questions Yet Another Re-Pricing for Opdivo, 11.5% Cut in August
May 12, 2021
- Fuji Yakuhin Out-Licenses Hyperuricemia Med Dotinurad to US Biotech
May 12, 2021
- Shionogi Chief Eyes Conditional Approval for COVID-19 Vaccine, Supply by Year’s End If OK’ed
May 11, 2021
- Chugai, Japan Govt Cut Supply Deal for COVID-19 Antibody Cocktail
May 11, 2021
- Takeda Submits Positive Japan Data for Approval-Pending Moderna Vaccine
May 11, 2021
- Shionogi Incurs Double-Digit Sales Fall in FY2020 as Infectious Disease Meds Falter
May 11, 2021
- Daiichi Sankyo’s DS-1062 Notches Positive PI Data in Triple Negative Breast Cancer
May 11, 2021
- Lawyer Hiroaki Tanaka Tapped to Lead Kobayashi Kako in Management Reshuffle
May 11, 2021
- Maruishi to Curb Supply of 5 Sedative Products due to Increase in Severe COVID-19 Cases
May 11, 2021
- Novartis Says Only 3,000 Pollen Allergy Patients Used Xolair This Season, Less than 10% of Re-Pricing Line
May 10, 2021
- Kyoto Startup to Begin Clinical Trial of iPSC-Derived Platelet Agent This Year, Eyes 10 Billion Yen Biz
May 10, 2021
- Kyowa Kirin’s Q1 Sales Rise on Strong Performance Overseas
May 10, 2021
- Positive Ruling for Shionogi Now Final and Binding: Osaka Tax Suit
May 10, 2021
- Astellas’ Xtandi Earns European Approval for HSPC
May 10, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…